SCHEMBL2634405

SCHEMBL2634405

CC(C)(C)[Si](C)(C)OC1CC=C(c2ccc(NC(=O)OCc3ccccc3)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 1/20 0.47
PDE3A Q14432 1/20 0.47
ROCK2 O75116 1/20 0.47
POLB P06746 1/20 0.46
KDM1A O60341 3/20 0.45
MAOA P21397 2/20 0.45
MAOB P27338 2/20 0.45
HRH3 Q9Y5N1 3/20 0.45
RCOR1 Q9UKL0 2/20 0.44
TP53 P04637 2/20 0.43
MAPT P10636 2/20 0.43
NPC1 O15118 2/20 0.43
ALDH1A1 P00352 2/20 0.43
TSHR P16473 2/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ATM Q13315 1/20 0.43
MGLL Q99685 3/20 0.42
PTGDR2 Q9Y5Y4 2/20 0.41
PRKDC P78527 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2635045 0.87 HRH3 (0.62) PDE3BPDE3AMAOBHRH3TP53
SCHEMBL14769158 0.82 KDM1A (0.47) PDE3BPDE3AROCK2POLBKDM1A
SCHEMBL14769166 0.80 KDM1A (0.53) PDE3BPDE3AROCK2POLBKDM1A
SCHEMBL29562161 0.79 KDM1A (0.49) PDE3BPDE3AROCK2POLBKDM1A
SCHEMBL5737794 0.76 SMN1; SMN2 (0.46) ROCK2POLBKDM1AMAOAMAOB
SCHEMBL2992039 0.75 ALDH1A1 (0.62) ALDH1A1TSHR
SCHEMBL2992037 0.75 ALDH1A1 (0.62) ALDH1A1TSHR
SCHEMBL5007203 0.75 ALDH1A1 (0.62) ALDH1A1TSHR
SCHEMBL328917 0.73 EPHX1 (0.57) ALDH1A1TSHR
SCHEMBL7805529 0.73 PTGDR2 (0.47) ROCK2POLBKDM1AMAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9453023-B2 Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof SANOFI (FR) 2016-09-27 US disclosed
US-9453023-B2 Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof SANOFI (FR) 2016-09-27 US disclosed
US-9453023-B2 Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof SANOFI (FR) 2016-09-27 US disclosed
EP-2569280-B1 Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof SANOFI SA (FR) 2015-02-25 EP disclosed
EP-2569280-B1 Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof SANOFI SA (FR) 2015-02-25 EP disclosed
US-20140275005-A1 SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-09-18 US disclosed
US-20140275005-A1 SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-09-18 US disclosed
US-20140275005-A1 SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-09-18 US disclosed
US-8735385-B2 Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof SANOFI (FR) 2014-05-27 US disclosed
US-8735385-B2 Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof SANOFI (FR) 2014-05-27 US disclosed
US-8735385-B2 Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof SANOFI (FR) 2014-05-27 US disclosed
EP-2569280-A1 SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-03-20 EP disclosed
US-20130065877-A1 SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-03-14 US disclosed
US-20130065877-A1 SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-03-14 US disclosed
WO-2011143150-A1 SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065877-A1 SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF PRLHR, TACR1, TACR2 PDE3B 1178/4885PDE3A 1065/4885ROCK2 2354/4885
US-20140275005-A1 SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF PRLHR, TACR1, TACR2 PDE3B 1178/4885PDE3A 1065/4885ROCK2 2354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.